New hope for Tough-to-Treat blood cancers: phase 3 trial launches
NCT ID NCT07516093
First seen Apr 21, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This study tests a new drug, NX-5948, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. About 620 adults whose cancer progressed after a previous BTK inhibitor therapy will be randomly assigned to one of the two drugs. The main goal is to see which drug better delays cancer growth or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.